Scientific Advisory Board
 

David Thomas, PhD

David has thirty years experience in biotechnology, fifteen of which were spent at major biopharmaceutical companies. His last position was as Senior Vice President Research & Development at Tanox, Inc. Before that, he was at Biogen as Director of Cell Biology and Immunology. He is an inventor on 64 patent publications and author of over 100 scientific publications in the area of immunology.
 

James W. Larrick , MD PhD

Jim has an international reputation in biotechnology having worked on various aspects of therapeutic antibodies and other protein therapeutics for the past 20 years. During this time he has written or co-authored eight books, over 220 papers/chapters and fifteen patents. He serves on the editorial board of six journals. Dr Larrick. Dr Larrick received his M.D. and Ph.D. degrees from Duke University School of Medicine, Durham, NC. After having completed a post-doctoral fellowship with Prof. Henry S. Kaplan in Stanford, he joined Cetus Immune Research Labs, Palo Alto, CA, where he became Director of Research in 1986. While at Cetus he pioneered the use of PCR for the construction of recombinant antibodies. In 1991, Dr Larrick founded the Palo Alto Institute of Molecular Medicine, a non-profit research institute situated near Stanford University. Since then he has founded more than a dozen biopharmaceutical companies including Kalobios  and  Nugen Technologies  in California and  PanGenetics B.V. and TargetQuest B.V. (merged with Dyax Inc.) in The Netherlands.  Currently  he serves on the Boards of five early stage companies and continues to pursue entrepreneurial activities through TENEX Medical Investors in Silicon Valley and 7X, an investment fund he co-founded in The Netherlands.
 

Randy Noelle, PhD

Randy is Professor of microbiology and immunology at Dartmouth Medical School and deputy director of the Norris Cotton Cancer Center, as well as co-director of the center's Immunology and Cancer Immunotherapy Research Program. He was a post-doctoral fellow at the University of Texas Health Science Center at Dallas from 1980-1984, and in 1984, he joined the faculty of Dartmouth Medical School as an Assistant Professor. In 1995, he was promoted to Professor of Microbiology. His laboratory has identified a novel membrane protein expressed on helper T lymphocytes (Th), CD154. Research is focused on how to block a wide spectrum of immune and autoimmune responses and transplantation rejection.
 

Flavio Vincenti, MD

Flavio is Professor of Clinical Medicine at UCSF, and is a kidney and pancreas transplant specialist.  He came to UCSF Medical Center in 1975 for a transplant nephrology fellowship and was appointed a member of the kidney transplant team.  His memberships in professional organizations include the American Society of Nephrology, American Society of Transplantation, International Society of Nephrology and Transplantation Society.  He is a co-leader of the kidney section of the Immune Tolerance Network for kidney transplantation.  In addition, he is on the editorial board of the American Journal of Kidney Diseases and Graft.  In 1978, Vincenti was one of the authors of an article in the New England Journal of Medicine about the role of blood transfusions in improving kidney transplants.  He also wrote a series of articles on the complications of transplants and has been a leading investigator and author on the use of anti-interleukin-2 receptor monoclonal antibodies.